FN2 Earnings Intelligence

JNJ earnings history

Johnson & Johnson (JNJ) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

Earnings History

Estimate Beat Miss Match
JNJ EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $2.66 Q1 '24 actual $2.71, beat Q2 '24 estimate $2.71 Q2 '24 actual $2.82, beat Q3 '24 estimate $2.21 Q3 '24 actual $2.42, beat Q2 '25 estimate $2.68 Q2 '25 actual $2.77, beat Q3 '25 estimate $2.76 Q3 '25 actual $2.80, beat Q4 '25 estimate $2.46 Q4 '25 actual $2.46, match Q1 '26 estimate $2.68 Q1 '26 actual $2.70, beat Q2 '26 estimate $2.84 Q2 '26 actual $2.90, beat Q3 '26 estimate $2.90 Q4 '26 estimate $3.02 Q1 '27 estimate $2.89 Q2 '27 estimate $3.12
Show 1 more >
JNJ FY2026 Q2 · Calendar Q3 2026

Johnson & Johnson

Johnson & Johnson delivered a solid Q2 2026 with $25.3 billion in sales (5.6% operational growth) and a $400 million raise in full-year guidance to a $101.1 billion midpoint. EPS of $2.90 beat the $2.84 consensus by 2.1%. The quarter was anchored by strong uptake of newly launched products across both Innovative Medicine (ICOTYDE, INLEXZO, RYBREVANT) and MedTech (VARIPULSE, vision lenses), with oncology remaining a primary growth engine through DARZALEX, CARVYKTI, and TALVEY. Despite the beat and raise, shares declined 2.7% on the report session, partially reflecting MedTech cardiovascular headwinds and STELARA biosimilar erosion, before recovering 7.7% over the subsequent period. Management's confident tone and continued pipeline execution (Firefly Bio acquisition, OTTAVA robotics, milvexian readout) reinforce the trajectory toward double-digit growth by decade's end.

EPS surprise+2.1%
Market move-2.7%